SBHMY News and Press, Sino Biopharmaceutical Ltd ADR From 09/01/21

While Precipio (PRPO) is a lesser-known company in the diagnostics and research industry, it generated significant market buzz in May 2021 when its COVID-19 antibody test became available on Amazon’s (AMZN) platform. However, can the stock continue to advance by relying on the antibody...

Penpulimab Monoclonal Antibody (PD-1) Obtains Marketing Approval in China PR Newswire HONG KONG , Aug. 5, 2021 /PRNewswire/ -- Akeso, Inc. (9926.HK, the "Company" or "Akeso") announced that the anti PD-1 monoclonal antibody drug Penpulimab monoclonal antibody ...

Sino Biopharmaceutical Donates Cash and Supplies Valued at RMB10 Million to Support Henan for Flood Relief and Preventing Epidemic HONG KONG, July 22, 2021 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiar...

Sino Biopharmaceutical 2021 First Quarterly Profit attributable to Owners of the Parent Soars 118.5% to RMB1.91 Billion HONG KONG, May 24, 2021 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Gr...

The COVID-19 pandemic brought a renewed interest to biotech firms, with many searching for treatments and vaccines. This led to strong returns for many top biotech stocks. But there are smaller, lesser know companies that are also poised for strong returns such as Vanda Pharmaceuticals (VNDA)...

Sino Biopharmaceutical 2020 Net Profit Grows to RMB2.77 Billion amid Adversity HONG KONG, Mar 23, 2021 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovati...

Genetron Holdings (GTH) and Chia Tai Tianqing Pharmaceutical Group, a subsidiary of Sino Biopharmaceutical (SBHMY) and a leading liver drug franchise with a major presence in liver disease hospitals in China entered in an exclusive strategic partnership agreement for HCCscreen,...

JD Health of Guangzhou, the online health-care arm of China e-commerce giant JD.com, completed a $3.5 billion Hong Kong IPO and rose 56% in its first trading session. Beijing's Sinovac Biotech reported Sino Biopharma of Hong Kong will invest $515 million in a Sinovac subsidiary to dou...

Sinovac Biotech has developed a successful COVID-19 vaccine, CoronaVac, directly competing with two Chinese rivals, Pfizer, AstraZeneca, Moderna and Russia's Sputnik V. Nasdaq and Hong Kong-listed partner Sino Biopharm providing $515 million funding for 15.03% equity stake in Sinovac....

Sino Biopharm Invests in Sinovac LS, A Leading COVID-19 Vaccine Company in China HONG KONG, Dec 7, 2020 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Group"; HKEX: 1177) has announced the investment of US$515 million in Sinovac Life Sciences Co., L...